We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 g/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 g/kg/day). reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.
reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis. Keywords: PBSC; acute leukemia; purging; autologous transplantation Autologous transplantation of mobilized circulating stem cells (PBSC) is being increasingly used in place of conventional ABMT as consolidation treatment for leukemia patients in complete remission (CR). Compared to BMderived stem cells, reinfusion of autologous PBSC following myeloablative conditioning regimens has reduced the period of marrow aplasia and reduced morbidity, mortality and resource utilization. [1] [2] [3] [4] [5] [6] Despite these encouraging results, disease relapse remains the most frequent cause of treatment failure for acute leukemia patients undergoing autologous stem cell transplantation. In this respect, earlier studies [7] [8] [9] and our own more recent experience 10 have failed to detect tumor cells in the PB of leukemic subjects during the early recovery phase from remission induction/ consolidation chemotherapy. However, the high disease relapse rate previously described 1, 3, 11 suggests that reinfusion of a larger quantity of cells to patients than in conventional ABMT may increase the probability of returning leukemic cells. The issue of leukemia-free autografting has recently been emphasized by gene-marking studies which demonstrated the contribution of residual contaminating tumor cells to disease relapse. 12 Moreover, evidence of the clinical relevance of purging strategies based on alkylating agents with regard to remission duration and/or survival has been accumulating over the years. [13] [14] [15] [16] [17] [18] [19] [20] We have recently described 21 an experimental model for ex vivo purging of leukemic cells from PBSC collections that combines the use of the alkylating agent nitrogen mustard (NM) and VP-16 which had previously been shown to act synergistically on leukemia cell lines with no increased toxicity on BM progenitors. 22 The results of our preclinical studies demonstrated the anti-tumor efficacy of NM/VP-16. Moreover, despite different kinetic characteristics, 23 BM and circulating progenitor cells, including primitive longterm culture-initiating cells (LTC-IC), did not show any dif-ference in their sensitivity to purging agents. Thus, steadystate BM samples could be safely used as a predictive test for individual dose-adjustment of alkylating drugs. We now report the results of a pilot study aimed at evaluating the feasibility of dose-adjusted pharmacological purging of PBSC from high-risk leukemia patients and to assess the engraftment and the hematopoietic reconstitution of patients who received autologous-purged PBSC after myeloablative treatment.
Whereas the clinical results associated with this purging procedure should be evaluated in a larger series of patients, the data presented here indicate the rapid and sustained hematological recovery of leukemia patients reinfused with leukapheresis products treated ex vivo.
Patients and methods

Patient characteristics and treatment
From January 1995 to December 1997, 12 consecutive individuals (seven females and five males) with a median age of 46 years (range 18-57) entered the study, and their clinical characteristics are shown in Table 1 . The protocol was approved by the University Hospital ethical committee and each patient gave written informed consent. The diagnoses of acute leukemia and mantle cell lymphoma were made according to the French-American-British (FAB) 24 and REAL 25 classifications, respectively. At time of PBSC collection, two patients had acute myeloblastic leukemia (AML) partially resistant to conventional induction treatment, two AML individuals were in I complete remission (CR) achieved after three or more cycles of induction treatment while one patient was in II CR and had been reinduced after failing autologous BM transplantation. Four additional patients with secondary AML (following myelodysplastic syndrome n = 3 or anti-cancer treatment n = 1) were in I CR. Two patients with high-risk acute lymphobl- astic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome at diagnosis (Table 1) AML patient underwent PBSC aphereses at the time of rapid hematological recovery after consolidation treatment. They received granulocyte colony-stimulating factor (G-CSF, filgrastim; Dompè Biotec, Milan, Italy) subcutaneously at a dose of 5 g/kg/day starting on day +13 from the end of chemotherapy and administered until the completion of PBSC collection.
Two ALL patients achieved CR following the administration of the L-20 protocol. 26 Afterwards, in steady-state condition, they received 7.5 g/kg/twice a day of G-CSF subcutaneously for 6-7 days to mobilize CD34 + cells into PB. Similarly, AML patient No. 9 was treated with G-CSF alone. The patient with mantle cell lymphoma was first treated with the MACOP-B regimen 27 and subsequently with two courses of FLAN chemotherapy and G-CSF for PBSC mobilization.
Leukapheresis procedures and PBSC processing
PBSC harvest was undertaken in all but three individuals after achievement of CR whereas patients Nos 1, 7 and 10 had residual marrow disease. Patients mobilized with chemotherapy and G-CSF underwent leukaphereses when the CD34 + cell count exceeded 10 000/ml. When G-CSF was given alone, apheresis collections were started on day 5. As already reported, 28 circulating stem cells were collected by using either a Fenwal CS3000 continuous flow blood cell separator (Baxter, Rome, Italy) with the modified procedure N. 1 program or a Cobe Spectra separator (Cobe BCT, Lakewood, CO, USA) to obtain a minimum yield of 2 ϫ 10 6 CD34 + cells/kg. One to three apheresis products (median number per patient, n = 2) were treated with NM/VP-16 whereas one additional leukapheresis (у1 × 10 8 MNC/kg) was stored as unmanipulated backup to be reinfused in case of delayed hematological recovery after transplantation. PBSC were cryopreserved, thawed and reinfused as reported elsewhere. 29 Ex vivo treatment VP-16 (Bristol Mayers-Squibb, Latina, Italy) was supplied in 5-ml ampules at a concentration of 20 mg/ml, and dilutions were made with RPMI-1640 immediately before each treatment. NM (Mustargen, Merck Sharp, Glattbrugg, Switzerland) was reconstituted and diluted immediately before use with phosphate-buffered saline (PBS) without calcium and magnesium. Pharmacological purging was performed according to the experimental protocol previously published. 21 Briefly, PB cells were adjusted to a concentration of 20 ϫ 10 6 /ml. The hematocrit was always less than 5%. VP-16 was used at a constant dose of 20 g/ml while the individual dose-adjusted concentration of NM (defined as the dose capable of sparing р5% granulocyte-macrophage colony-forming unit, CFU-GM) was established by incubating steady-state BM cells with increasing concentrations (0.1-1.5 g/ml) of the drug. PBSC collections were incubated with NM/VP-16 combination for 1 h at 37°C with frequent agitation. After completion of incubation, cells were placed on ice for 5 min to halt the reaction and washed twice with RPMI-1640 containing 1% human albumin.
Assessment of hematopoietic progenitor cells
The number of CD34 + cells was determined as previously described. 23, 28 Briefly, 5 ϫ 10 5 nucleated cells were stained with an anti-CD34 mouse-derived monoclonal antibody (MoAb) IgG2a-fluorescein isothyocyanate (FITC) (HPCA-2; Becton Dickinson, San Jose, CA, USA) for 20 min at 4°C. A IgG isotype was used as control. After two washes, flow-cytometric analysis was performed on a gated population set on scatter properties by using FACScan equipment (Becton Dickinson). A minimum of 100 000 events were collected in list mode on FACScan software.
Samples of PB were evaluated in semisolid assay to determine the CFU-GM content as reported elsewhere. 23, 28 Cells were plated in duplicate in culture medium consisting of 1 ml of Iscove's modified Dulbecco's medium (IMDM; GIBCO-BRL, Paisley, UK), supplemented with 24% of fetal calf serum (FCS; GIBCO), 1% glutamine and antibiotics and 10% (v/v) selected phytohemagglutinin-lymphocyte-conditioned medium (PHA-LCM). Final methylcellulose concentration was 1.1%. CFU-GM colonies were scored after 14 days of incubation at 37°C in a fully humidified 5% CO 2 atmosphere.
Conditioning regimen and PBSC transplantation
Acute leukemia patients received a myeloablative regimen consisting of busulfan 4 mg/kg/day for 4 days and cyclophosphamide (Cy) 60 mg/kg/day given for 2 days associated with Uromitexan (Mesna, Asta Medica, Milan, Italy). . 31 At the time of stem cell reinfusion (day 0), each bag was thawed and infused via a central line. 29 
Supportive care and hematological recovery
All patients were nursed in reverse isolation single rooms until hospital discharge and received antimicrobial prophylaxis that consisted of oral nystatin and ciprofloxacin. Broad-spectrum intravenous antibiotics were promptly instituted in cases of fever Ͼ38.5°C during neutropenia. Platelet support was given when the platelet count was р10 ϫ 10 9 /l. Packed red cells were administered at a hemoglobin level р8 g/dl. Hematopoietic growth factors were not routinely administered to patients.
The primary clinical end point of the study was time to hematopoietic reconstitution, which was defined as the number of days to achieve a granulocyte count greater than 0.5 ϫ 10 9 /l (first of 3 consecutive days) and an unsupported platelet count greater than 20 and 50 ϫ 10 9 /l.
Results
PBSC mobilization and NM/VP-16 purging
Twelve patients entered the study and nine had their circulating stem cells collected at the time of hematological recovery after the first (NOVIA regimen; n = 3) or the second (FLAN; n = 6) cycle of consolidation therapy (Table  1) . In these patients, G-CSF administration was initiated at day +13 from the end of chemotherapy and leukaphereses were started when CD34 + cell and platelet counts were у10 and 20 ϫ 10 9 /l, respectively. Furthermore, patient No. 9 achieved I CR after four cycles of chemotherapy and subsequently underwent PBSC mobilization with G-CSF alone. Similarly, two additional ALL individuals received, in steady-state conditions, the growth factor for stem cell collection. In these cases PBSC harvest was started on day +5. Cytogenetic analysis performed on leukapheresis products revealed a normal karyotype even in those patients with residual marrow disease (Nos. 1, 7, 10) (data not shown).
A median of two aphereses (range 1-3) allowed the collection of 7.2 ϫ 10 8 TNC/kg (range 3.4-11.5), 5 ϫ 10 6 CD34 + cells/kg (range 2.1-15.3) and 9.2 ϫ 10 4 CFU-GM/kg (0.3-236) ( Table 2) . As for stem cell mobilization, there was no difference between patients who had their PBSC collected after one or two courses of consolidation therapy or G-CSF alone. PBSC were treated with a constant dose of 20 g of VP-16/ml and NM according to a dose-response curve performed on steady-state BM cells. The median individualadjusted dose (survival р5% of BM CFU-GM) of NM was 0.7 g/ml (range 0.25-1.25) ( Table 3) .
PBSC transplantation and hematopoietic recovery
Eleven patients have been reinfused to date (Table 3 ). The median time from CR to transplantation (when applicable) was 4 months (range 1-7). Administration of busulfan (16 mg/kg) and Cy (120 mg/kg) was followed by the reinfusion of a median dose of 6. due to absolute neutropenia associated with fungal pneumonia. Tables 4 and 5 show engraftment results, supportive care and clinical follow-up of the study patients. For evaluable subjects, the median time to ANC Ͼ0.5 ϫ 10 9 /l was 25 days (range 12-59); the median time to platelet transfusion independence (Ͼ20 and Ͼ50 ϫ 10 9 /l) was 40 days (18-95) and 69 days (29-235), respectively. Due to the rather rapid hematopoietic recovery, transfusion requirement and use of parenteral antibiotics were limited (Table 5 ). Neutrophil and/or platelet recovery was not observed mainly in those patients who either died early after transplantation (Nos 4, 7, 8) or showed early disease recurrence (No. 5). Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion.
Transplant toxicity and disease status
Two heavily pretreated patients (Nos 4 and 8) died early in the peritransplant period due to extrahematological toxicity (Table 5 ). Four individuals are alive in CR (n = 3) or with residual nodal disease (NHL patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died from disease progression (n = 2) or relapse (n = 5). Patient No. 12 relapsed 40 days after PBSC collection before autologous transplantation and he has recently been admitted to hospital for reinduction with FLAN chemotherapy.
Discussion
Autologous bone marrow transplantation (ABMT) is widely used as consolidation treatment for leukemia patients in CR who lack a suitable HLA-matched sibling donor. [32] [33] [34] [35] [36] [37] [38] Leukemia-free survival (LFS) rates for AML individuals in I CR range from 33 to 68% and these results do not significantly differ, in randomized studies, from those achieved with allogeneic stem cell transplantation. 39 However, delayed hematological recovery occurs in a substantial proportion of patients after ABMT causing signifi- cant morbidity and mortality. In this respect, we have recently reported 40 51 adult AML patients autotransplanted in late I CR with unmanipulated BM cells who showed a median time to 0.5 ϫ 10 9 neutrophils/l and 20 ϫ 10 9 platelets/l of 26 (range 12-250) and 74 (range 16-740) days, respectively. Thus, we 41 and others [1] [2] [3] [4] [5] [6] [7] [8] [9] have addressed the question of whether the use of PBSC might result in a more rapid engraftment in AML patients. Whereas it has been demonstrated that the reinfusion of circulating stem cells induces faster hematopoietic reconstitution, lower transfusion requirement and shorter hospitalization than transplantation of BM cells, 1,2,6,41 preliminary results suggest a higher relapse rate after PBSC autograft 1,3,11 perhaps due to the reinfusion of occult contaminating leukemia cells. 12 In this paper we report the results of a pilot study on 12 leukemia patients at high-risk of relapse who were transplanted with chemotherapy-purged autologous PBSC. The aims of our clinical trial were: (1) to evaluate the feasibility of dose-adjusted pharmacological purging of mobilized stem cells; and (2) to assess the hematopoietic reconstitution of patients receiving ex vivo treated PBSC after Bu/Cy conditioning regimen. Ex vivo treatment was performed by combining the alkylating agent NM and VP-16, as previously described. 22 This purging strategy was shown to be effective in eliminating leukemia cell lines contaminating PBSC collections while sparing a significant proportion of hematopoietic progenitor cells including primitive longterm culture-initiating cells (LTC-IC). 21 Moreover, an individual dose-adjustment of NM was used to optimize leukemia cell killing and to reduce hematopoietic toxicity in vivo. 14, 42, 43 All the patients entered in the study achieved, with a median of two aphereses, the minimum number of 2 ϫ 10 6
CD34
+ cells required to proceed to purging. In six patients, PBSC were collected after the second consolidation course (FLAN regimen) to take advantage of the in vivo purging exerted by chemotherapy.
Based on our preclinical studies 21 we hypothesized that a reliable predictive assessment of hematopoietic toxicity of NM/VP-16 treatment could be made by testing BM samples before PBSC mobilization. Notably, we reinfused a median number of 0.3 ϫ 10 4 CFU-GM/kg which represents approximately 3% of the initial content of clonogenic progenitors of leukaphereses. We thus reinforced, in vivo, the concept that despite a different distribution into the cell cycle, 23 BM and circulating progenitor cells do not appear to differ in their sensitivity to purging protocols involving NM7VP-16. This finding needs confirmation when different alkylating agents (ie Cy derivatives) are used. In addition, given the significantly lower percentage of Sphase cells, 23 mobilized CD34 + cells may actually be less sensitive to S-phase-specific drugs such as Ara-C than marrow cells.
Hematological reconstitution was evaluable in nine patients surviving beyond 30 days from autologous transplantation. Neutrophil recovery occurred at a median of 25 days after reinfusion of PBSC compared to 26 and 17 days (range 11-46) in patients who received, in our institution, unpurged BM 40 or PB cells, 41 respectively, following Bu/Cy (P = 0.05 when unpurged PBSC are compared with treated PBSC). Similarly, platelet transfusion independence was achieved after 40 days in comparison with 74 (P Ͻ 0.05) and 28 days (range 10-180; P = NS) of the same individuals undergoing BM 40 or PBSC autograft, 41 respectively. Despite all the limitations of a retrospective analysis performed on a small series of patients, these data suggest that pharmacological purging may to a limited extent affect the period of myeloaplasia, following stem cell transplantation, with respect to unmanipulated PBSC. In addition, when compared to conventional ABMT, NM/VP-16 purging does not affect the superiority of circulating stem cells in inducing much faster platelet recovery. Moreover, the rather rapid hematological reconstitution translated into limited requirement for blood products support, parenteral antibiotics and a short hospital stay. One patient (No. 11) was reinfused with untreated backup cells at day +25 with a ANC Ͻ0.2 ϫ 10 9 /l and potentially life-threatening pulmonary aspergillosis was diagnosed.
Laporte et al 16, 44 have recently described the long-term experience of the Paris group on mafosfamide-purged ABMT for leukemia 16 and myelodysplasia patients. The authors reported the reinfusion of 1 log less CFU-GM than in the present study. Accordingly, neutrophil and platelet recovery was substantially delayed. 16, 44 Perhaps more importantly, they identified the number of CFU-GM in the BM harvest as one of the more important parameters correlating with LFS. 16 Taken together, these results may suggest the use of PBSC instead of conventional BM cells when purging is important. In our series, three out of 10 leukemia patients are alive in CR after 32, 26 and 3 months from transplantation. Design of the study as well as size of patient sample do not allow any meaningful conclusion on the anti-leukemic efficacy of this protocol. Nonetheless, our results suggest that the feasibility of a prospective randomized study to demonstrate clinical use of ex vivo purging, which is still needed, may be improved by use of purged PBSC as well as by addition of amifostine to reduce toxicity of alkylating agents on hematopoietic progenitors. 45 Although several retrospective clinical studies supporting the role of alkylating agent-based purging strategies have been reported, [13] [14] [15] [16] [17] [18] [19] [20] many investigators may be prevented from participating in randomized trials due to major concerns about both prolonged myeloaplasia after transplantation and difficulties in harvesting sufficient cells from the BM to proceed to purging. Notably, our preclinical studies 21 demonstrated that the more conventional cyclophosphamide derivative mafosfamide was at least as effective as the NM/VP-16 combination for eliminating minimal residual disease from PBSC collections and, therefore, could be safely used in those transplant centers with a historical control group of patients who have received mafosfamide-treated BM cells.
In summary, our results suggest that chemical purging does not prevent PBSC-mediated hematological reconstitution in leukemia patients. Further studies are warranted to demonstrate the clinical impact of this strategy.
